Table 1.
Baseline characteristics of patients included in the study
| Lipid poor adenoma (n = 13) | Pheochromocytoma (n = 35) | Adrenocortical carcinoma (n = 15) | Metastatic infiltration/infection (n = 9) | |
|---|---|---|---|---|
| Age | 36 (23-51) | 40 (30-52) | 36 (22-39) | 52 (50-67) |
| Sex (male/female) | 3/10 | 17/18 | 5/10 | 7/2 |
| Biochemical evaluation (%) | ||||
| Only cortisol hypersecretion | 5/13 (38.5) | 0/35 (0) | 6/15 (40) | 0/9 (0) |
| Aldosterone hypersecretion | 2/13 (15.4) | 0/35 (0) | 1/15 (6.7) | 0/9 (0) |
| Androgen hypersecretion | 1/13 (7.6) | 0/35 (0) | 1/15 (6.7) | 0/9 (0) |
| Cortisol and androgen hypersecretion | 0/13 (0) | 0/35 (0) | 5/15 (33.3) | 0/9 (0) |
| PFNMN hypersecretion | 0/13 (0) | 20/35 (57.1) | 0/15 (0) | 0/9 (0) |
| PFMN hypersecretion | 0/13 (0) | 10/35 (28.6) | 0/15 (0) | 0/9 (0) |
| Imaging | ||||
| Good washout (RPW ≥ 40%)/poor washout (RPW < 40%) | 9/4 | 15/20 | 1/14 | 0/9 |
| Largest diameter (cm) | 3.4 (2.8-3.7) | 5.9 (5.0-7.0) | 11.3 (9.0-15.4) | 5.1 (3.9-9.9) |
| Left/right | 6/7 | 16/19 | 8/7 | 3/6 |
| Necrosis (%) | 4/13 (30.8) | 24/35 (68.6) | 15/15 (100) | 3/9 (33.3) |
| Hemorrhage (%) | 0/13 (0) | 2/35 (5.7) | 2/15 (13.3) | 0/9 (0) |
| Calcification (%) | 0/13 (0) | 3/35 (8.6) | 4/15 (26.7) | 1/9 (11.1) |
| Enhancement patterns (HU) | ||||
| Plain | 30.8 (21.3-36.1) | 36.6 (34.6-41.9) | 42.2 (35.5-43.3) | 37.2 (31.8-38.4) |
| Arterial | 69.7 (56.4-81.7) | 130.9 (91.9-173.0) | 60.4 (55.2-91.6) | 46.6 (37.4-71.1) |
| Venous | 82.7 (76.8-93.8) | 107.8 (82.2-124.8) | 69.7 (62.4-81.9) | 63.4 (58.9-87.1) |
| Delayed | 52.7 (38.0-59.1) | 66.7 (58.3-75.5) | 55.1 (49.9-61.7) | 59.9 (50.6-70.9) |
| Washout patterns (%) | ||||
| APW | 60.4 (48.2-70.1) | 61.2 (50.7-66.5) | 53.8 (36.5-66.7) | 32.8 (7.0-64.3) |
| APW > 60% | 7/13 (53.8) | 18/35 (51.4) | 6/15 (40) | 3/9 (33.3) |
| RPW | 40.9 (23.9-50.7) | 38.9 (26.3-45.5) | 25.1 (11.8-29.9) | 17.3 (3.2-24.1) |
| Indices | ||||
| PAE (%) | 162.9 (97.9-200.5) | 237.4 (110.8-392.6) | 49.3 (33.9-124.4) | 43.4 (5.9-95.2) |
| PVE (%) | 229.0 (144.3-298.4) | 193.0 (93.1-256.2) | 79.8 (53.3-104.3) | 77.8 (59.0-132.2) |
| Aortic arterial (HU) | 254.2 (207.8-309.2) | 260.6 (208.0-289.9) | 249.6 (216.8-350.9) | 256.3 (222.2-321.9) |
| Arterial HU of mass/aorta | 0.28 (0.22-0.32) | 0.49 (0.35-0.67) | 0.26 (0.20-0.32) | 0.18 (0.12-0.25) |
| Arterial HU > venous HU by ≥5 (%) | 1/13 (7.7) | 26/35 (74.3) | 4/15 (26.7) | 1/9 (11.1) |
| Arterial HU > venous HU by ≥10 (%) | 1/13 (7.7) | 23/35 (65.7) | 3/15 (20) | 1/9 (11.1) |
Data is expressed as n/N (%) or median (interquartile range).
Abbreviations: APW, absolute percentage washout; HU, Hounsfield unit; PAE, percentage arterial enhancement; PFMN, plasma free metanephrine; PFNMN, plasma free normetanephrine; PVE, percentage venous enhancement; RPW, relative percentage washout.